Abingdon Health PLC Director Dealing (5334U)
April 06 2021 - 7:34AM
UK Regulatory
TIDMABDX
RNS Number : 5334U
Abingdon Health PLC
06 April 2021
Director Dealing
York, U.K. 6(th) April 2021: Abingdon Health (AIM:ABDX)
("Abingdon" or "the Company"), a leading international developer
and manufacturer of high quality and effective rapid tests,
announces that Melanie Ross, Chief Financial Officer, has today
purchased 5,338 ordinary shares of 0.025p each in the Company
("Ordinary Shares") at a price of 93.45 pence per Ordinary Share.
Prior to this, Melanie did not hold an interest in any Ordinary
Shares, and therefore has a resultant interest in 0.01% of the
Company's issued share capital.
- Ends-
Enquiries:
Abingdon Health
plc
Chris Yates Chief Executive Officer Via Consilium
Melanie Ross Chief Financial Officer
Chris Hand Non-Executive Chairman
N+1 Singer Sole Broker and Nominated Adviser
Tel: +44 (0) 20 7496
Shaun Dobson, Peter Steel, 3000
Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Tel: +44 (0) 203 709
Consilium Financial PR 5700
Matthew Neal abingdonhealth@consilium-comms.com
Mary-Jane Elliott
Lindsey Neville
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
https://www.abingdonhealth.com/
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Melanie Ross
------------------------------------- ------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------
a) Name Abingdon Health plc
------------------------------------- ------------------------------------------
b) LEI 213800XFI4WV3FBILO20
------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------- ------------------------------------------
c) Price(s) and volume(s)
--------------------- ----------------
Price(s) Volume(s)
--------------------- ----------------
93.45 pence 5,338
---------------------------------------------------------------- ----------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
e) Date of the transaction 6 April 2021
------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange
------------------------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBDGDSBXGDGBL
(END) Dow Jones Newswires
April 06, 2021 08:34 ET (12:34 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
